Sensus Healthcare

Sensus Healthcare is a medical device company that designs, manufactures and sells superficial radiation therapy (SRT) systems — low-energy X-ray devices used as a non-surgical alternative for treating non-melanoma skin cancers including basal cell and squamous cell carcinoma, as well as keloids and other dermatological conditions. Its product line spans the SRT-100, the SRT-100 Vision system with embedded high-frequency ultrasound imaging and treatment planning, and the SRT-100+, supported by the Sentinel service programme and a Transdermal Infusion system. The company sells primarily into private dermatology practices and to radiation oncologists in both private and hospital settings, and its commercial model is closely tied to US reimbursement: dedicated superficial-radiotherapy CPT codes took effect on 1 January 2026 and CMS has proposed a 26% increase in the hospital-based delivery code. Sensus was incorporated in 2010, is headquartered in Boca Raton, Florida, employs roughly 60 people and has traded on Nasdaq since its June 2016 IPO.